Frankfurt: Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.

The companies said in a statement the mRNA-based combination vaccine candidate was set to progress to a phase one trial in the United States with 180 volunteers.